Welcome to our dedicated page for Intra-Cellular Therapies news (Ticker: ITCI), a resource for investors and traders seeking the latest updates and insights on Intra-Cellular Therapies stock.
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. Company communications emphasize that it is founded on Nobel Prize-winning research into intracellular mechanisms and that this science underpins its work on complex psychiatric and neurologic diseases. News about ITCI often centers on its approved product CAPLYTA (lumateperone) and its expanding clinical pipeline.
Investors and observers following ITCI news will see updates on CAPLYTA, an oral, once-daily atypical antipsychotic approved in adults for the treatment of schizophrenia and for depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Recent company announcements have highlighted financial results driven by CAPLYTA net product sales, as well as clinical and regulatory milestones such as a supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration for adjunctive treatment of major depressive disorder (MDD).
ITCI news flow also includes detailed clinical trial readouts and conference presentations. The company has reported positive Phase 3 data from Studies 501 and 502 evaluating lumateperone as adjunctive therapy in MDD, Phase 3 results in the prevention of relapse in schizophrenia, and multiple late-stage trials in bipolar disorder, pediatric populations, and other CNS indications. Additional updates cover progress in the ITI-1284-ODT-SL program in generalized anxiety disorder and Alzheimer’s disease-related psychosis and agitation, the PDE1 inhibitor program with lenrispodun (ITI-214) in Parkinson’s disease and ITI-1020 in oncology, and the ITI-1500 non-hallucinogenic neuroplastogen program.
Another important category of ITCI news involves corporate and strategic developments. Intra-Cellular Therapies and Johnson & Johnson have announced a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, with the transaction subject to regulatory and stockholder approvals. Legal and intellectual property news, including a settlement of CAPLYTA patent litigation with Sandoz, also features in company disclosures. For investors tracking ITCI, this news page aggregates earnings announcements, clinical data, regulatory submissions, patent settlements, and acquisition-related updates in one place.
Intra-Cellular Therapies (Nasdaq: ITCI) announced a conference call on March 1, 2022, at 8:30 a.m. ET to discuss its corporate updates and financial results for the year ending December 31, 2021. To participate, dial 1-(844) 835-6563 or 1-(970) 315-3916 internationally, using conference ID 5899935. The presentation will be available live and archived in the Investor Relations section on their website. Founded on Nobel prize-winning research, Intra-Cellular focuses on innovative treatments for CNS disorders.
Intra-Cellular Therapies (Nasdaq: ITCI) announced that CEO Sharon Mates, Ph.D., will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 8:40 am ET. Attendees can access the live and archived webcast through the Investor Relations section of the company's website. Intra-Cellular Therapies focuses on innovative treatments for central nervous system disorders, leveraging Nobel prize-winning research to understand cellular impacts of therapies. For more details, visit www.intracellulartherapies.com.
Intra-Cellular Therapies (Nasdaq: ITCI) has successfully completed a public offering of 9,523,810 shares at $42.00 each, raising approximately $460 million in gross proceeds. The underwriters fully exercised their option for an additional 1,428,571 shares. After deductions, the net proceeds amount to around $433.7 million. The offering was conducted under a shelf registration statement with the SEC. This infusion of capital aims to support the company's ongoing development of therapeutics for central nervous system disorders.
Intra-Cellular Therapies (ITCI) announced the pricing of a public offering of 9,523,810 shares at $42.00 each, totaling $400 million in gross proceeds. The offering will close on January 7, 2022, subject to customary conditions. Underwriters have a 30-day option to purchase an additional 1,428,571 shares. This is part of a shelf registration statement filed with the SEC. The funds raised will support ongoing development of CNS therapeutics, enhancing the company's financial position and growth prospects.
Intra-Cellular Therapies (Nasdaq: ITCI) has initiated a public offering of $400 million in shares of its common stock, with underwriters given a 30-day option to purchase an additional 15% of the shares. The offering is part of a shelf registration statement effective with the SEC. J.P. Morgan, SVB Leerink, and others are acting as joint book-running managers. The offering is subject to market conditions, with no assurance on completion or terms.
Intra-Cellular Therapies (ITCI), a biopharmaceutical company focused on treatments for central nervous system disorders, announced that CEO Sharon Mates, Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 10, 2022, at 7:30 AM ET. Investors can access the live and archived webcast through the company's website under the 'Events & Presentations' section. Intra-Cellular Therapies develops innovative therapies based on groundbreaking research to treat complex psychiatric and neurologic conditions.
Intra-Cellular Therapies announced FDA approval for CAPLYTA, the first treatment for depressive episodes associated with bipolar I and II disorder. CAPLYTA is approved as both monotherapy and adjunctive therapy with lithium or valproate. This approval is based on two positive Phase 3 studies showing significant improvements over placebo. Bipolar disorder affects about 11 million adults in the U.S., highlighting a significant unmet medical need. CAPLYTA offers a favorable safety and tolerability profile, making it a crucial treatment option for patients.
Intra-Cellular Therapies (Nasdaq:ITCI) announces the passing of Director Richard Lerner, MD, who contributed significantly to science and medicine. Dr. Lerner served on the board since 2002 and was influential in the company's mission to develop therapies for CNS disorders. His accolades include the Wolf Prize and membership in prestigious scientific academies. The company's leadership, including CEO Sharon Mates, expressed deep sadness and condolences to his family. Intra-Cellular Therapies focuses on innovative treatments for complex psychiatric and neurologic diseases, founded on Nobel Prize-winning research.
Intra-Cellular Therapies reported a remarkable 200% increase in total revenues for Q3 2021, totaling $22.2 million, driven by strong sales of CAPLYTA, which achieved $21.6 million in net product revenues. The company has completed its sales force expansion in preparation for the bipolar depression launch, pending FDA approval with a target date of December 17, 2021. Additionally, CAPLYTA's total prescriptions rose by 15% over the previous quarter. However, the net loss for Q3 grew to $76.9 million compared to $55.2 million a year ago.
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) will host a conference call on November 9, 2021, at 8:30 a.m. ET to discuss its financial results for Q3 2021 and provide a corporate update. Investors can access the call via phone or through a live webcast available on the company’s investor relations website. Intra-Cellular Therapies focuses on developing treatments for central nervous system disorders using innovative, research-backed methods.